A one-time treatment for patients with wet age-related macular degeneration (AMD) is gaining popularity in Europe. Oraya Therapy, made by US-based company Oraya Therapeutics, Inc., is being offered at more locations in Europe, including a National Health Service hospital in the UK and several hospitals in Germany.
Oraya Therapy has already been a regular treatment option in hospitals throughout Germany, the UK, and Switzerland, increasingly embraced by patients, doctors, and insurance providers. The one-time treatment is a non-invasive therapy for wet AMD patients meant to maintain or improve vision and decrease frequency of anti-vascular endothelial growth factor (anti-VEGF) eye injections.
Anti-VEGF injections are a conventional and commercially available treatment for wet AMD, but the required frequency of injections poses a burden to patients who are often not able to receive the optimal number of treatments.
Oraya Therapy attempts to lessen the number of injections through a low-radiation treatment that can be performed in an outpatient setting in about 20 minutes, with no further recovery period required. Success of the treatment has been demonstrated by the INTREPID study, which indicated successful results for wet AMD patients both immediately following and two years after the single treatment.